Wilson MR, Wasserman MD, Breton MC, Peloquin F, Earnshaw SR, McDade C, Sings HL, Farkouh RA. Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: a retrospective analysis. Infect Dis Ther. 2020 Aug;9(2):341-53. doi: 10.1007/s40121-020-00294-6
Wilson M, Wasserman M, Breton MC, Peloquin F, McDade C, Earnshaw S, Farkouh R. Estimating the clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Quebec. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Ottawa, Canada.
Wasserman M, Wilson M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Previously presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases.
Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018 Sep;7(3):353-71. doi: 10.1007/s40121-018-0206-1
Wilson M, Wasserman M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 16, 2018. Melbourne, Australia.
Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017 Mar 24;2017(12):997-1008.
Wilson M, Wasserman M, Breton MC, McDade C, Earnshaw S, Farkouh R. Potential clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Canada. Poster presented at the 2016 Canadian Immunization Conference; December 6, 2016. Ottawa, Canada.
Wilson M, Lim J, Gandhi P, Wang C, Sander S, McDade C, Earnshaw S. Economic analysis of oral anticoagulants in the prevention of vascular events in Medicare patients with nonvalvular atrial fibrillation. Poster presented at the 38th Annual North American Meeting of the Society for Medical Decision Making; October 25, 2016. Vancouver, Canada.
Wilson MR, Gutierrez B, Offord S, Blanchette CM, Eramo A, Earnshaw SR, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273
Patel J, Coleman A, Wilson M, McDade C, Carr S, Earnshaw S. Budgetary impact on a U.S. health plan after adopting umeclidinium/vilanterol (UMEC/VI) for the management of moderate-to-severe COPD. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr 7; 21(4a):S55.
Kamat SA, Blanchette C, Wilson MR, Tangirala M, Earnshaw SR, Offord S, Gutierrez B, Eramo A, Baker RA. Healthcare cost savings associated with aripiprazole once-monthly (AOM) treatment among schizophrenia patients with psychiatric hospitalizations prior to AOM treatment initiation. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.
Wilson MR, Gutierrez B, Offord S, Zhao C, Beillat M, Eramo A, Earnshaw SR. Total healthcare cost-offset associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Poster presented at the US Psychiatric & Mental Health Congress; September 2013.
Earnshaw SR, Wilson M, Mauskopf J, Joshi AV. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Value Health. 2009 Jun 1;12(4):507-20.
Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med. 2009 Jan 1;103(1):12-21.
Earnshaw SR, Wilson MR, Blanchette C. Cost-effectiveness of salmeterol/fluticasone propionate in the treatment of COPD: estimating the annual number of exacerbations in chronic obstructive pulmonary disease. Poster presented at the Annual Meeting of the American College of Chest Physicians; October 2007.
Earnshaw SR, Okazawa M, Wilson MR, Blanchette C. Estimating the annual number of exacerbations in chronic obstructive pulmonary disease. Poster presented at the International Conference of the American Thoracic Society; May 2007.
Earnshaw SR, Wilson MR, Joshi AV. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage over a two-year managed care enrollment period. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. [abstract] Value Health. 2007 May; 10(2):A182. Previously presented at the 2006 International Stroke Conference.
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006 Nov 28;37(11):2751-8.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage. Poster presented at the 2006 International Stroke Conference; February 17, 2006. [abstract] Stroke. 2006 Nov; 37(11):2751.
Earnshaw SR, Wilson MR, Joshi AV. Budgetary impact analysis of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US health plan perspective. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A329.
Earnshaw SR, Wilson MR, Joshi AV. Short-term cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Value Health. 2006 May 1;9(3):A8.
Earnshaw SR, Joshi AV, Wilson MR. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US managed care perspective. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 7, 2006.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.
Pignone M, Earnshaw S, Tice JA, Pletcher M, Wilson M. Aspirin, statins, or both therapies for primary prevention of myccardial infarction: a cost-utility analysis. J Gen Intern Med. 2004 Jan 1;19:121.